RxDoctor Payments Data

Shipra Shah, MD

Internal Medicine · Wayne, NJNPI 1154689156

Payments from drug & device makers

$189in general payments, 2019–2025

Across 12 payments — averaging $15.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$44
  • AstraZeneca$38
  • Qorumpartners$23
  • Gilead$20
  • AbbVie$19
  • Johnson & Johnson$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk3$44
AstraZeneca3$38
Qorumpartners1$23
Gilead1$20
AbbVie1$19
Johnson & Johnson1$17
Merck1$15
Novartis1$14

How this compares

$189 in reported general payments places this provider in the 40th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$452,059
Medicare patients
268
Services billed
7,544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide74$80,958
EliquisApixaban42$36,092
JanuviaSitagliptin Phosphate30$32,723
OzempicSemaglutide28$30,127
RybelsusSemaglutide23$29,609
JardianceEmpagliflozin21$22,110
XareltoRivaroxaban11$17,071
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$15,646
Repatha SureclickEvolocumab12$14,847
VascepaIcosapent Ethyl20$6,968
CrestorRosuvastatin Calcium11$5,442
DuleraMometasone/Formoterol12$3,801
SynthroidLevothyroxine Sodium24$2,365
Rosuvastatin Calcium105$2,285
Atorvastatin Calcium208$1,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$44$59,73651 claims
MerckJanuvia, Dulera$15$36,52442 claims
Johnson & JohnsonXarelto$17$17,07111 claims
AstraZenecaCrestor$38$5,44211 claims
AbbVieSynthroid$19$2,36524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →